Scholar Rock to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company specializing in treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and diseases involving protein growth factors, has announced its participation in four major investor conferences in March:

• TD Cowen 45th Annual Health Care Conference - March 4 in Boston (fireside chat at 2:30 p.m. ET)
• Wedbush Cardiometabolic Conference - March 10 in Miami (panel presentation at 10:05 a.m. ET)
• Jefferies Biotech on the Bay Summit - March 11 in Miami (1x1 meetings)
• BMO Obesity Summit - March 25 in New York City (panel presentation at 1:15 p.m. ET)

A live webcast of the Cowen presentation will be available on the company's investor website, with replay access for approximately 90 days.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences:

• TD Cowen 45^th Annual Health Care Conference: Scholar Rock is scheduled to participate in a fireside chat at 2:30 p.m. ET on Tuesday, March 4 in Boston.
• Wedbush Cardiometabolic Conference: Scholar Rock is scheduled to participate in a panel presentation at 10:05 a.m. ET on Monday, March 10 in Miami.
• Jefferies Biotech on the Bay Summit: Scholar Rock management will participate in 1x1 meetings on Tuesday, March 11 in Miami.
• BMO Obesity Summit: Scholar Rock is scheduled to participate in a panel presentation at 1:15 p.m. ET on Tuesday, March 25 in New York City.

A live webcast of the Cowen presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days.

About Scholar Rock

Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.

This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at ScholarRock.com and follow @ScholarRock and on LinkedIn.

Scholar Rock® is a registered trademark of Scholar Rock, Inc.

Availability of Other Information About Scholar Rock

Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250225740002/en/

Scholar Rock:

Investors

Rushmie Nofsinger

Scholar Rock

rnofsinger@scholarrock.com

ir@scholarrock.com

857-259-5573



Media

Molly MacLeod

Scholar Rock

mmacleod@scholarrock.com

media@scholarrock.com

802-579-5995

Source: Scholar Rock

FAQ

What investor conferences will Scholar Rock (SRRK) attend in March 2024?

SRRK will attend four conferences: TD Cowen Health Care Conference (March 4), Wedbush Cardiometabolic Conference (March 10), Jefferies Biotech Summit (March 11), and BMO Obesity Summit (March 25).

Where can investors watch Scholar Rock's TD Cowen conference presentation?

Investors can watch the live webcast through Scholar Rock's investor website (investors.scholarrock.com). A replay will be available for 90 days.

What therapeutic areas does Scholar Rock (SRRK) focus on?

Scholar Rock focuses on spinal muscular atrophy (SMA), cardiometabolic disorders, and diseases where protein growth factors play key roles.

Which of Scholar Rock's March 2024 presentations will be available via webcast?

Only the TD Cowen Health Care Conference presentation on March 4 will be available via webcast.

What types of investor interactions will SRRK have at these March conferences?

SRRK will participate in fireside chats, panel presentations, and one-on-one meetings across the different conferences.